Literature DB >> 9487022

The role of alpha-melanocyte-stimulating hormone in cutaneous biology.

T A Luger1, T Scholzen, S Grabbe.   

Abstract

alpha-Melanocyte stimulating hormone is a neuroimmunomodulating peptide that was recently detected in many non-pituitary tissues including the skin. Accordingly, epidermal cells such as keratinocytes and melanocytes (as well as dermal cells such as fibroblasts and endothelial cells), after stimulation with pro-inflammatory cytokines or UV light, synthesize, and release alpha MSH. The effects of these peptides are mediated through specific melanocortin (MC) receptors that can be detected on immunocompetent and inflammatory cells as well as on keratinocytes, melanocytes, fibroblasts, and endothelial cells. In addition to its well known pigment-inducing capacity, alpha MSH is able to modulate keratinocyte proliferation and differentiation. Endothelial cell and fibroblast cytokine production and fibroblast collagenase production are also regulated by alpha MSH. The immunosuppressive capacity of alpha MSH is mediated mainly through its effects on monocyte and macrophage functions. Accordingly, alpha MSH downregulates the production of pro-inflammatory cytokines and accessory molecules on antigen-presenting cells. The production of suppressor factors such as IL-10, however, is upregulated by alpha MSH. The in vivo relevance of these data is documented by the finding that systemic application of alpha MSH inhibits the induction and the elicitation of murine contact hyper-sensitivity and induces hapten-specific tolerance. These findings indicate that alpha MSH is part of the mediator network that regulates cutaneous inflammation and hyper-proliferative skin diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9487022     DOI: 10.1038/jidsymp.1997.17

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  22 in total

Review 1.  Regulation of melanocyte pivotal transcription factor MITF by some other transcription factors.

Authors:  Ping Wan; Yongqing Hu; Li He
Journal:  Mol Cell Biochem       Date:  2011-04-26       Impact factor: 3.396

Review 2.  Without nerves, immunology remains incomplete -in vivo veritas.

Authors:  Andrew J Shepherd; James E G Downing; Jaleel A Miyan
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

3.  Expression of galanin and galanin receptor mRNA in skin during the formation of granulation tissue.

Authors:  Hiroyuki Yamamoto; Takeo Arai; Shinta Ben; Kazuaki Iguchi; Minoru Hoshino
Journal:  Endocrine       Date:  2011-09-06       Impact factor: 3.633

Review 4.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism.

Authors:  Liang Dong; Ji Wen; Eric Pier; Xiao Zhang; Bo Zhang; Fangzheng Dong; Nick Ziegler; Margaret Mysz; Rafael Armenta; Rutao Cui
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Alpha-melanocyte stimulating hormone inhibits monocytes adhesion to vascular endothelium.

Authors:  Yang Yang; Weihua Zhang; Lin Meng; Haitao Yu; Na Lu; Gang Fu; Yang Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-20

7.  Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair.

Authors:  M T Bastiaens; J A ter Huurne; C Kielich; N A Gruis; R G Westendorp; B J Vermeer; J N Bavinck
Journal:  Am J Hum Genet       Date:  2001-03-16       Impact factor: 11.025

8.  The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature.

Authors:  G Leoni; M-B Voisin; K Carlson; Sj Getting; S Nourshargh; M Perretti
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

9.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

10.  The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells.

Authors:  La'Verne P Rennalls; Thomas Seidl; James M G Larkin; Claudia Wellbrock; Martin E Gore; Tim Eisen; Ludovica Bruno
Journal:  Immunology       Date:  2010-01-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.